Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
145M
-
Shares change
-
+28.7M
-
Total reported value, excl. options
-
$134M
-
Value change
-
+$26.6M
-
Put/Call ratio
-
0.4
-
Number of buys
-
55
-
Number of sells
-
-20
-
Price
-
$0.93
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q2 2023
96 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q2 2023.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 145M shares
of 1.57B outstanding shares and own 9.21% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (39M shares), BAILLIE GIFFORD & CO (17.2M shares), NEA Management Company, LLC (17.1M shares), BAKER BROS. ADVISORS LP (11M shares), PFM Health Sciences, LP (8.36M shares), Long Focus Capital Management, LLC (7.81M shares), MPM ASSET MANAGEMENT LLC (6.29M shares), BIOIMPACT CAPITAL LLC (5.1M shares), TANG CAPITAL MANAGEMENT LLC (4.89M shares), and BANK OF AMERICA CORP /DE/ (4.7M shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.